Evidence map›Paper›PMID 41309963›Full record

ArticleScientific reports2025

Molecular recognition of natural compounds by MR1 and their implication in MAIT cell activation elucidated through McMD-based dynamic docking simulations.

Gert-Jan Bekker, Mitsugu Araki, Kanji Oshima, Yasushi Okuno, Narutoshi Kamiya

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gert-Jan BekkerInstitute for Protein Research, University of Osaka, 3-2 Yamadaoka, Suita, Osaka, 565-0871, Japan. gertjan.bekker@protein.osaka-u.ac.jp.ORCID 0000-0001-8385-5693
Mitsugu ArakiGraduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.ORCID 0000-0002-7810-4905
Kanji OshimaBio-Pharma Research Laboratories, KANEKA CORPORATION, 1-8 Miyamae-cho, Takasago-cho, Takasago, Hyogo, 676-8688, Japan.
Yasushi OkunoGraduate School of Medicine, Kyoto University, 53 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.ORCID 0000-0003-3596-4208
Narutoshi KamiyaGraduate School of Information Science, University of Hyogo, 7-1-28 Minatojima Minami-machi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. n.kamiya@sim.u-hyogo.ac.jp.ORCID 0000-0002-0527-6968

Funding

Japan Agency for Medical Research and Development 24ae0121028h0004Japan Society for the Promotion of Science JP20H03229Japan Society for the Promotion of Science,Japan JP25K09585
6 · The paper itself

Abstract

Major histocompatibility complex class I-related protein 1 (MR1), presents bacteria-derived ligands to T cell receptors (TCRs) as antigens as a defense against bacterial infections through activation of mucosal-associated invariant T cells (MAIT cells). Since mammals do not produce riboflavin (RBF, vitamin B2) themselves, unlike bacteria, MR1 can present the intermediates of RBF synthesis as a marker of non-self to initiate an immune response. Here, we have performed multicanonical molecular dynamics-based dynamic docking simulations to analyze the binding mechanism of RBF and two of its derivatives, photolumazine I (PLI) and III (PLIII) with MR1. We found that PLI and PLIII bind with high specificity in a manner similar to a known high-affinity ligand, RL-6-Me-7-OH. In contrast, RBF binds in multiple less specific, non-productive configurations. Subsequent structural analyses revealed that PLI and PLIII support productive TCR engagement and MAIT cell activation, while RBF fails to activate MAIT cells. Consequently, an immune response is triggered against PLI and PLIII, but not against RBF. These findings uncover the distinct binding mechanisms between the three compounds and MR1 and highlight their differential effects on MAIT cell activation in the context of bacterial infection.

Indexed as

Histocompatibility Antigens Class ILymphocyte ActivationMinor Histocompatibility AntigensMucosal-Associated Invariant T CellsRiboflavinAnimalsHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingReceptors, Antigen, T-CellHistocompatibility Antigens Class ILigandsMinor Histocompatibility AntigensMR1 protein, humanReceptors, Antigen, T-CellRiboflavinBinding mechanismMHC class I-related protein 1Mucosal-associated invariant T cellsMulticanonical molecular dynamics simulationNatural small molecule compounds

Identifiers

PMID41309963
PMCPMC12749305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.